Psilocybin-Assisted Therapy : A Review of a Novel Treatment for Psychiatric Disorders Kelan Thomas, Pharm.D., M.S., Benjamin Malcolm, Pharm.D., M.P.H., and Dan Lastra, B.S. Journal of Psychoactive Drugs, 2017 Doi : 10.1080/02791072.2017.1320734 Abstract Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psycho-pathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have reviewed the current literature to investigate the efficacy and safety of psilocybin-assisted therapy for the treatment of psychiatric disorders. There were [...]
Lire la suiteThe Religious Significance of Entheogenic Drugs Hugh Asher More Info: This is my unpublished Master's Dissertation. Abstract This paper examines the use of psychoactive substances such as Psilocybin, Mescaline, and LSD as adjuncts to mystical, religious or spiritual experiences. There is an analysis of the psychological changes and the changes in perception that these substances cause and how these can be interpreted as contributing to religious or spiritual enlightenment. There is also a discussion on the nature of what could be considered a religious experience. An overview of the use of such ‘entheogenic’ drugs from an historical perspective follows, looking specifically at the use of [...]
Lire la suitePsychological Explorations of the Magic Mushroom (Psilocybin) Experience, Part I : Subjective Effects and Time Passage Perception José Arturo Costa Escobar, M.S., Antonio Roazzi, Ph.D. Neurobiologia, 2011, 74, (3-4), 81-97. ABSTRACT Magic mushrooms are rich in the active compound psilocybin, whose activity on consciousness deeply alters cognitive functions, can promote spiritual/mystical experiences and has high biomedical and psychotherapeutic importance. Twenty-eight participants underwent a magic mushroom experience after consuming dehydrated Psilocybe cubensis mushrooms at the dosage of 55.6 mg/Kg (350 μg/kg of psilocybin). Results of subjective aspects of the experience through the Hallucinogen Rating Scale revealed equivalent dosage effects comparable to other studies and similar [...]
Lire la suiteTherapeutic Applications of Ayahuasca and Other Sacred Medicines Michael J. Winkelman chapter 1, in B. Caiuby Labate and C. Cavnar (eds.) : "The Therapeutic Use of Ayahuasca", Springer-Verlag Berlin Heidelberg 2014 Doi : 10.1007/978-3-642-40426-9_1 Abstract : Therapeutic applications of the psychedelics or hallucinogens found cross-culturally involve treatment of a variety of physical, psychological, and social maladies. Modern medicine has similarly found that a range of conditions may be successfully treated with these agents. The ability to treat a wide variety of conditions derives from variation in active ingredients, doses and modes of application, and factors of set and setting manipulated in ritual. Similarities in effects reported [...]
Lire la suitePsilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, and Franz X. Vollenweider Biological Psychiatry, 2014. http://dx.doi.org/10.1016/j.biopsych.2014.04.010 Background : The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. Methods : This study assessed the effects of [...]
Lire la suitePatient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis and Stephen Ross Journal of Humanistic Psychology, 2017, 1 –35 Doi : 10.1177/0022167817706884 journals.sagepub.com/home/jhp Abstract The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitative research regarding psilocybin, the current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy. Semistructured interviews were carried out with 13 adult participants aged 22 to 69 years (M = 50 years) with clinically elevated anxiety associated with a cancer [...]
Lire la suiteBIBLIOGRAPHIE : Psilocybes, psilocybine. Dr Christian SUEUR, GRECC, décembre 2019 Psilocybes, psilocybine : généralités ..............................1 Psilocybes : ethnologie ...................................................2 Psilocybine : clinique psychiatrique ..............................4 Psilocybine : pharmacologie ..........................................5 Psilocybine : toxicologie - "effets indésirables" .............7 Psilocybine : neurophysiologie ......................................9 Psilocybine : expériences mystiques .............................13 Psilocybine : thérapie psychédélique ............................15-19
Lire la suiteThe mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity Rainer Kraehenmann, André Schmidt, Karl Friston, Katrin H. Preller, Erich Seifritz, Franz X. Vollenweider NeuroImage : Clinical, 2016, 11, 53–60 http://dx.doi.org/10.1016/j.nicl.2015.08.009 a b s t r a c t Stimulation of serotonergic neurotransmission by psilocybin has been shown to shift emotional biases away from negative towards positive stimuli. We have recently shown that reduced amygdala activity during threat processing might underlie psilocybin's effect on emotional processing. However, it is still not known whether psilocybin modulates bottom-up or top-down connectivity within the visual-limbic-prefrontal network underlying threat processing.We therefore analyzed our previous fMRI data using [...]
Lire la suiteThe psychedelic renaissance : the next trip for psychiatry ? J. R. Kelly, A. Baker, M. Babiker, L. Burke, C. Brennan and V. O’Keane Irish Journal of Psychological Medicine, 2019, 1 - 5 doi : 10.1017/ipm.2019.39 Abstract The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological support, have indicated improvements in mood, anxiety and quality of life. A seminal, open-label study demonstrated marked reductions in depression symptoms in participants with treatment-resistant depression (TRD). The associated neurobiological processes involve alterations in brain connectivity, together with altered amygdala and default mode network activity. At the cellular level, psychedelics promote [...]
Lire la suiteSerotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in endstage cancer Rafael Guimarães dos Santos, José Carlos Bouso and Jaime E. C. Hallak BMC Psychiatry, 2019, 19, 321 https://doi.org/10.1186/s12888-019-2288-z Abstract In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and spirituality. However, evidence showing that classic or serotonergic hallucinogens/psychedelics such as psilocybin and lysergic acid diethylamide (LSD) could be effective treatments for depressive and anxiety disorders in end-stage cancer was not included. In [...]
Lire la suite